Millipore, Proteome Sciences Sign Licensing Agreement

Published: 06-Jul-2009

To develop innovative research tools to advance the study of Alzheimer's disease

Proteome Sciences and Millipore have signed an exclusive license agreement to develop new products that will help to advance the study of Alzheimer's disease. Under the terms of the agreement, Millipore will develop Luminex bead-based multiplex immunoassays, to measure Proteome Sciences' proprietary Alzheimer's disease biomarkers.

Millipore would acquire the exclusive right to develop and sell Luminex bead-based panels for research related to the study of Alzheimer's disease and other cognitive function disorders. Proteome Sciences retains all rights to clinical applications of these biomarkers.

Financial terms of the license agreement were not yet disclosed.

Christopher Pearce, CEO of Proteome Sciences, said: We are pleased to be working with Millipore. We see this as a key step in the development of clinical tests for Alzheimer's disease. These diagnostics will help scientists more precisely diagnose and monitor Alzheimer's disease in its early stages, which are critically important.

Jonathan DiVincenzo, President of Bioscience Division at Millipore, said: This collaboration will help us achieve our broader goal of advancing the study of neurobiology and neurodegenerative diseases. By expanding our portfolio of multiplex immunoassays targeting Alzheimer's disease biomarkers, we will complement our portfolio of products for neuroscience that includes antibodies and ELISAs, neural stem cells, specialty media, and cell-based high content analysis kits. The development of a comprehensive multiplex Alzheimer's panel will accelerate research and ultimately lead to better monitoring as a clinical tool.

Tell your friend about this article